In terms of hematological malignancies, the effects of IL-33 are controversial as a negative role has been identified for Chronic myelogenous leukemia (CML), while a positive role was shown for Acute myeloid leukemia (AML) (Allegra et al., 2019). This evidence concerns the gene IL33 and acute myeloid leukemia.